Last reviewed · How we verify
TR987 0.1% gel + Standard of Care — Competitive Intelligence Brief
phase 3
Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
TR987 0.1% gel + Standard of Care (TR987 0.1% gel + Standard of Care) — TR Therapeutics. TR987 0.1% gel works by targeting the existing mechanism of standard of care to enhance its effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TR987 0.1% gel + Standard of Care TARGET | TR987 0.1% gel + Standard of Care | TR Therapeutics | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TR987 0.1% gel + Standard of Care CI watch — RSS
- TR987 0.1% gel + Standard of Care CI watch — Atom
- TR987 0.1% gel + Standard of Care CI watch — JSON
- TR987 0.1% gel + Standard of Care alone — RSS
Cite this brief
Drug Landscape (2026). TR987 0.1% gel + Standard of Care — Competitive Intelligence Brief. https://druglandscape.com/ci/tr987-0-1-gel-standard-of-care. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab